Hepatitis C: Diagnosis and Treatment
- ️Thad Wilkins|Jennifer K. Malcolm|Dimple Raina|Robert R. Schade
THAD WILKINS, MD; JENNIFER K. MALCOLM, DO; DIMPLE RAINA, MD; and ROBERT R. SCHADE, MD, Medical College of Georgia, Augusta, Georgia.
Am Fam Physician. 2010 Jun 1;81(11):1351-1357.
A more recent article on hepatitis C is available.
Patient information: See related handout on hepatitis C, written by the authors of this article.
Hepatitis C, a common chronic bloodborne infection, is found in approximately 2 percent of adults in the United States. Chronic infection is associated with serious morbidity and mortality (e.g., cirrhosis, hepatocellular carcinoma). Testing for hepatitis C is recommended for at-risk populations, and confirmatory testing includes quantification of virus by polymerase chain reaction. The U.S. Preventive Services Task Force recommends against routine screening for hepatitis C virus infection in asymptomatic adults who are not at increased risk of infection (general population). It found insufficient evidence to recommend for or against routine screening in adults at high risk of infection. Current therapy for chronic hepatitis C virus includes pegylated interferon and ribavirin. Therapy is based on factors that predict sustained virologic response, and the goal of therapy is to slow or halt progression of fibrosis and prevent the development of cirrhosis. In the future, multidrug regimens in combination with current therapies may be developed. Patients with chronic hepatitis C virus infection should be advised to abstain from alcohol use. Currently, there is no vaccine available to prevent hepatitis C virus infection; however, persons infected with hepatitis C virus should be vaccinated for hepatitis A and B. The American Association for the Study of Liver Diseases recommends ultrasound surveillance for hepatocellular carcinoma in persons with chronic hepatitis C virus infection and cirrhosis.
An estimated 170 million persons, or 3 percent of the world’s population, are chronically infected with the hepatitis C virus (HCV).1 In the United States, the prevalence of hepatitis C antibody is 2 percent in adults 20 years and older, but the prevalence is higher in groups at increased risk (e.g., 8 to 9 percent in persons undergoing hemodialysis).2,3 HCV, a single-stranded RNA virus, is transmitted through percutaneous exposure to infected blood.4 HCV is categorized into nine genetically distinct genotypes.5 In the United States, 72 percent of patients with HCV infection have genotype 1; 16 to 19 percent have genotype 2; 8 to 10 percent have genotype 3; and 1 to 2 percent have other genotypes.6 This article focuses on chronic HCV infection in adults and excludes special groups, such as children, pregnant women, transplant recipients, and persons coinfected with hepatitis B virus (HBV) or human immunodeficiency virus (HIV).
SORT: KEY RECOMMENDATIONS FOR PRACTICE
| Clinical recommendation | Evidence rating | References |
|---|---|---|
Persons who are not at increased risk (general population) should not be screened for HCV infection. | A | |
Persons with HCV infection should be vaccinated for hepatitis A and B. | C | |
Persons with chronic HCV infection should abstain from alcohol consumption. | C | |
Hepatotoxic drugs should be avoided in persons with chronic HCV infection and cirrhosis. | C | |
Surveillance for hepatocellular carcinoma should be considered in persons with chronic HCV infection and cirrhosis. | C | |
The standard therapy for chronic HCV infection is pegylated interferon and ribavirin (Rebetol). | C* |
SORT: KEY RECOMMENDATIONS FOR PRACTICE
| Clinical recommendation | Evidence rating | References |
|---|---|---|
Persons who are not at increased risk (general population) should not be screened for HCV infection. | A | |
Persons with HCV infection should be vaccinated for hepatitis A and B. | C | |
Persons with chronic HCV infection should abstain from alcohol consumption. | C | |
Hepatotoxic drugs should be avoided in persons with chronic HCV infection and cirrhosis. | C | |
Surveillance for hepatocellular carcinoma should be considered in persons with chronic HCV infection and cirrhosis. | C | |
The standard therapy for chronic HCV infection is pegylated interferon and ribavirin (Rebetol). | C* |
Pathophysiology
The most common sources of HCV transmission are exposure to blood products before HCV testing procedures were routine; sharing of contaminated needles among injection drug users; and reuse of incompletely sterilized needles, syringes, or other medical equipment.1,4,7 Risk factors for exposure to HCV are shown in Table 1.8 Blood transfusions in the United States after 1992 have a very low risk of transmitting HCV (three per 10,000 units transfused).9
Table 1
Risk Factors for Exposure to Hepatitis C Virus
| Risk factor | Odds ratio |
|---|---|
Intravenous drug use | 36 |
Sex with intravenous drug user | 17 |
Hemodialysis | 8.3 |
Male sex | 3.1 |
Blood transfusion | 2.3 |
Sex with multiple partners | 2.2 |
Surgery | 1.0 |
White or Hispanic race | 0.9 |
Age 40 to 60 years | 0.8 |
Needlestick injury | 0.7 |
Health care occupation | 0.3 |
Vaccinated for hepatitis B | 0.3 |
Table 1
Risk Factors for Exposure to Hepatitis C Virus
| Risk factor | Odds ratio |
|---|---|
Intravenous drug use | 36 |
Sex with intravenous drug user | 17 |
Hemodialysis | 8.3 |
Male sex | 3.1 |
Blood transfusion | 2.3 |
Sex with multiple partners | 2.2 |
Surgery | 1.0 |
White or Hispanic race | 0.9 |
Age 40 to 60 years | 0.8 |
Needlestick injury | 0.7 |
Health care occupation | 0.3 |
Vaccinated for hepatitis B | 0.3 |
Screening and Prevention
The U.S. Preventive Services Task Force recommends against routine screening for HCV infection in asymptomatic adults who are not at increased risk of infection (general population). It found insufficient evidence to recommend for or against routine screening for HCV infection in adults at high risk of infection because no studies have proven that testing leads to a reduction in HCV-related morbidity and mortality.2,10 A cohort study of 25,701 patients found that targeted screening leads to early identification of persons at increased risk of complications from HCV and those who may benefit from antiviral therapy (number needed to screen = 451).11
There is no vaccine available to prevent HCV infection. Patients with HCV infection should be considered for hepatitis A and B vaccination because of the increased risk of morbidity and mortality with coinfection.4,12 HCV is not efficiently transmitted, and the average rate of seroconversion after an occupational exposure to HCV-positive blood through accidental needlestick is 1.8 percent.13 Persons should be tested for HCV following exposure through an accidental needlestick. Although there is no evidence to support the use of immune globulin therapy after an accidental needlestick,13 a small case series of 44 patients suggests that treatment of persons with acute HCV infection may prevent progression to chronic HCV infection.14
Injection drug users should avoid needle sharing because it is the strongest independent risk factor for HCV infection.2 An association between HCV infection and high-risk sexual behavior may be because of a high rate of sexual transmission or because high-risk sexual behaviors are a marker for unacknowledged drug use.2 Persons at risk should use latex condoms with sexual activity.12
Diagnosis and Complications
Most patients (60 to 70 percent) with HCV infection are asymptomatic; when symptoms do occur, they are non-specific and include fatigue, nausea, anorexia, myalgias, arthralgias, weakness, and weight loss.1,7,12 Abnormal laboratory findings or signs of cirrhosis should prompt HCV antibody testing, followed by confirmatory tests.2
Chronic HCV infection leads to cirrhosis in about 10 to 20 percent of patients, increasing the risk of complications of chronic liver disease, including portal hypertension, ascites, hemorrhage, and hepatocellular carcinoma.1,3 Factors associated with disease progression to cirrhosis include male sex, developing HCV infection when older than 40 years, HIV or HBV coinfection, immunosuppression, and daily alcohol consumption of at least 50 g (approximately three drinks per day).15,16 Alcohol consumption and HCV act synergistically to promote the progression of liver damage. Persons with HCV infection who drink alcohol on a regular basis have a higher rate of fibrosis and cirrhosis.16,17 The American Association for the Study of Liver Diseases (AASLD) recommends that persons with chronic HCV infection abstain from alcohol consumption.15 Hepatotoxic drugs should be avoided in persons with chronic HCV infection and cirrhosis.3
Persons with HCV infection and cirrhosis have a 20-fold increased risk of hepatocellular carcinoma compared with persons without HCV infection.18 Although uncommon in the United States (incidence of 8,500 to 11,500 cases per year), the incidence has increased approximately 70 percent in the past 30 years, and the prognosis is poor, with a median survival of eight months.19,20 A recent meta-analysis found that ultrasound surveillance of persons at increased risk of hepatocellular carcinoma had a pooled sensitivity of 94 percent and specificity of 94 percent (positive likelihood ratio = 15.7; negative likelihood ratio = 0.1).21 However, ultrasonography was less effective for detecting early hepatocellular carcinoma, with a sensitivity of only 63 percent.21 The AASLD recommends surveillance for hepatocellular carcinoma in persons with chronic HCV infection and cirrhosis based largely on a randomized study involving 18,816 patients with chronic HBV infection, which showed a 37 percent mortality reduction at one year favoring surveillance versus no surveillance.18,22 However, there are no studies showing that ultrasound surveillance improves morbidity or mortality from hepatocellular carcinoma.
Diagnostic Testing
Diagnostic tests used for the detection of HCV infection include the HCV antibody enzyme immunoassay, recombinant immunoblot assay, and quantitative HCV RNA polymerase chain reaction (PCR). Table 2 lists common diagnostic tests,15,23 and Table 3 lists the diagnostic precision of various tests.2,24–27 The most widely used initial assay for detecting HCV antibodies is the enzyme immunoassay. A positive enzyme immunoassay should be followed by a confirmatory test. When used in low-risk groups, an enzyme immunoassay may yield false-positive results.24 A saliva-based test for HCV antibody detection may soon be available.25 Recombinant immunoblot assay, a confirmatory test for a positive enzyme immunoassay, detects antibodies to individual HCV antigens and has a greater specificity.26 It is used in conjunction with viral load tests to distinguish between a resolved infection and a false-positive enzyme immunoassay.
Table 2
Diagnostic Tests and Test Results in Suspected HCV Infection
| Initial anti-HCV tests | Confirmatory HCV tests | Test interpretation | |
|---|---|---|---|
| Enzyme-linked immunosorbent assay* | Recombinant immunoblot assay | HCV RNA polymerase chain reaction | |
Negative | — | — | No infection or very early infection (repeat polymerase chain reaction if clinical suspicion of acute HCV infection) |
Positive | Positive | Positive | Current infection |
Positive | Negative | Negative | False-positive antigen test |
Positive | Positive | Negative | Past infection with HCV |
Table 2
Diagnostic Tests and Test Results in Suspected HCV Infection
| Initial anti-HCV tests | Confirmatory HCV tests | Test interpretation | |
|---|---|---|---|
| Enzyme-linked immunosorbent assay* | Recombinant immunoblot assay | HCV RNA polymerase chain reaction | |
Negative | — | — | No infection or very early infection (repeat polymerase chain reaction if clinical suspicion of acute HCV infection) |
Positive | Positive | Positive | Current infection |
Positive | Negative | Negative | False-positive antigen test |
Positive | Positive | Negative | Past infection with HCV |
Table 3
Diagnostic Precision of Laboratory Tests for HCV Infection
| Test | Sensitivity (%) | Specificity (%) | Positive likelihood ratio | Negative likelihood ratio | Positive predictive value* (%) | Negative predictive value* (%) |
|---|---|---|---|---|---|---|
Recombinant immunoblot assay† | 79 | 80 | 3.95 | 0.26 | 7.5 | 99.5 |
Saliva-based anti-HCV | 87 | 99 | 87 | 0.13 | 64 | 99.7 |
Anti-HCV‡ | 94 to 100 | 97 to 98 | 31 to 49 | 0.06 to 0.01 | 39 to 50.4 | 99.9 to 100 |
HCV RNA polymerase chain reaction§ | 96 | 99 | 96 | 0.04 | 66.2 | 99.9 |
Table 3
Diagnostic Precision of Laboratory Tests for HCV Infection
| Test | Sensitivity (%) | Specificity (%) | Positive likelihood ratio | Negative likelihood ratio | Positive predictive value* (%) | Negative predictive value* (%) |
|---|---|---|---|---|---|---|
Recombinant immunoblot assay† | 79 | 80 | 3.95 | 0.26 | 7.5 | 99.5 |
Saliva-based anti-HCV | 87 | 99 | 87 | 0.13 | 64 | 99.7 |
Anti-HCV‡ | 94 to 100 | 97 to 98 | 31 to 49 | 0.06 to 0.01 | 39 to 50.4 | 99.9 to 100 |
HCV RNA polymerase chain reaction§ | 96 | 99 | 96 | 0.04 | 66.2 | 99.9 |
Quantitative viral load tests measure the amount of virus in blood. Quantitative studies provide information on initial viral load, viral load reduction with therapy, and a sustained virologic response, defined as undetectable HCV by PCR six months after stopping therapy.15 However, HCV RNA levels do not correlate directly with liver injury, duration of infection, or disease severity.
Treatment
The goal of therapy is to slow or halt progression of fibrosis and prevent the development of cirrhosis, thereby helping patients live longer, symptom-free lives.28 Sustained virologic response is the surrogate marker used by most studies to evaluate the effectiveness of therapy and is associated with improved outcomes, such as low likelihood of viral relapse, reduced mortality, and reduced risk of cirrhosis and hepatocellular carcinoma.29,30 Table 4 lists virologic responses to treatment of HCV infection.15,31 All persons with chronic HCV infection should be considered candidates for treatment; however, several factors influence the decision to proceed with therapy.32 Nonmodifiable factors, such as the presence of genotype 1, a high viral load, obesity, black or Latino race, advanced age, and the degree of liver fibrosis, indicate a lower probability of response to therapy.33,34 Treatment for HCV infection is widely accepted in persons at least 18 years of age who are willing to be treated and to conform to treatment requirements, with abnormal serum alanine transaminase (ALT) values, significant liver fibrosis or compensated cirrhosis, and normal renal function, and without anemia or neutropenia.32
Table 4
Virologic Response to Treatment for HCV Infection and Recommendations to Discontinue Therapy
| Interpretation of quantitative HCV RNA | Virologic response | Decision to continue or discontinue treatment |
|---|---|---|
Undetectable virus at week 4 of treatment | Rapid virologic response (predictive of sustained virologic response) | Consider early discontinuation for genotype 1a or 1b at week 24 if viral load < 600,000 IU per mL and for genotype 2 or 3 at weeks 12 to 16 because these levels are highly predictive of sustained virologic response |
More than 100-fold decrease in viral load at week 12 of treatment | Partial virologic response | Recheck viral load at week 24; if undetectable, continue treatment until week 48 If detectable, consider prolonged treatment until week 72 |
Undetectable virus at week 12 of treatment | Complete virologic response | Continue treatment until week 48 |
Stable viral load or failure to achieve more than 100-fold decrease in viral load at week 12 of treatment | Nonresponse | Discontinue treatment |
Undetectable viral load six months after ending treatment | Sustained virologic response | HCV infection eradicated |
Table 4
Virologic Response to Treatment for HCV Infection and Recommendations to Discontinue Therapy
| Interpretation of quantitative HCV RNA | Virologic response | Decision to continue or discontinue treatment |
|---|---|---|
Undetectable virus at week 4 of treatment | Rapid virologic response (predictive of sustained virologic response) | Consider early discontinuation for genotype 1a or 1b at week 24 if viral load < 600,000 IU per mL and for genotype 2 or 3 at weeks 12 to 16 because these levels are highly predictive of sustained virologic response |
More than 100-fold decrease in viral load at week 12 of treatment | Partial virologic response | Recheck viral load at week 24; if undetectable, continue treatment until week 48 If detectable, consider prolonged treatment until week 72 |
Undetectable virus at week 12 of treatment | Complete virologic response | Continue treatment until week 48 |
Stable viral load or failure to achieve more than 100-fold decrease in viral load at week 12 of treatment | Nonresponse | Discontinue treatment |
Undetectable viral load six months after ending treatment | Sustained virologic response | HCV infection eradicated |
[ corrected] A detailed history and examination should be performed to identify contraindications to therapy (Table 5).32 Before starting therapy, baseline blood work should be obtained, including a complete blood count, complete metabolic panel, and measurement of thyroid-stimulating hormone level, because interferon therapy is associated with leukopenia, thrombocytopenia, and autoimmune thyroiditis. Persons with chronic HCV infection and anemia, renal insufficiency, autoimmune hepatitis, decompensated cirrhosis, pregnancy, severe cardiopulmonary disease, uncontrolled major depression, or untreated hyperthyroidism are not good candidates for treatment.32 Blood urea nitrogen and serum creatinine levels should be evaluated because ribavirin (Rebetol) is renally excreted and should be used with caution in patients with renal insufficiency.
Table 5
Contraindications to Treatment for Chronic HCV Infection
Absolute contraindications |
Active autoimmune hepatitis or other condition known to be exacerbated by interferon and ribavirin (Rebetol) |
Known hypersensitivity to drugs used to treat HCV infection |
Pregnant or unwilling to comply with adequate contraception |
Renal failure (contraindicated for ribavirin only) |
Severe concurrent cardiopulmonary disease |
Uncontrolled major depressive illness, psychosis, or bipolar disorder |
Untreated hyperthyroidism |
Relative contraindications |
Decompensated cirrhosis:
|
Baseline hematologic and biochemical indices:
|
Table 5
Contraindications to Treatment for Chronic HCV Infection
Absolute contraindications |
Active autoimmune hepatitis or other condition known to be exacerbated by interferon and ribavirin (Rebetol) |
Known hypersensitivity to drugs used to treat HCV infection |
Pregnant or unwilling to comply with adequate contraception |
Renal failure (contraindicated for ribavirin only) |
Severe concurrent cardiopulmonary disease |
Uncontrolled major depressive illness, psychosis, or bipolar disorder |
Untreated hyperthyroidism |
Relative contraindications |
Decompensated cirrhosis:
|
Baseline hematologic and biochemical indices:
|
Serum aspartate transaminase (AST) and ALT levels may be normal in 10 to 40 percent of patients with chronic HCV infection.12 Although there is a poor correlation between serum ALT level and severity of liver disease, monthly monitoring of AST and ALT levels is recommended during treatment for HCV infection and at three and six months following treatment.12 A scoring system using platelet count and AST and albumin levels predicts severe fibrosis with 99 percent specificity and 94 percent positive predictive value.35 Genotype identification assists in predicting response to treatment because persons with genotype 1 have lower rates of response to therapy than patients with genotypes 2 and 3.36 Liver biopsy to assess disease severity may be considered when deciding whether to initiate treatment in patients with chronic HCV infection and persistently normal transaminase levels or with relative contraindications to therapy, or for prognostic purposes (e.g., in patients with genotype 1).12,26
Treatment Options
Standard therapy for the treatment of chronic HCV infection is pegylated interferon and ribavirin.37,38 Oral ribavirin monotherapy is not effective for inducing sustained virologic response (relative risk = 1.01; 95% confidence interval, 0.96 to 1.07).39 There are two formulations of pegylated interferon that are approved for HCV therapy: pegylated interferon alfa-2a (Pegasys) and pegylated interferon alfa-2b (Pegintron). Sustained virologic response rates for pegylated interferon monotherapy and pegylated interferon plus ribavirin are 25 to 39 percent and 54 to 60 percent, respectively (number needed to treat = 1.7 to 1.9 for sustained virologic response for pegylated interferon plus ribavirin, compared with placebo).2 A recent randomized controlled trial compared pegylated interferon alfa-2b plus ribavirin with pegylated interferon alfa-2a plus ribavirin and found no statistical difference for sustained virologic response.40
The duration of therapy is determined by HCV genotype and virologic response to therapy. In general, patients with genotypes 1 and 4 are treated for 48 weeks, and those with genotypes 2 and 3 are treated for 24 weeks.15 Table 6 lists the recommended drugs and duration of treatment for HCV infection based on genotype.32,41 The quantitative HCV RNA level is used to assess response to therapy and as a guide to discontinue treatment. A negative viral load test after four weeks of therapy is predictive of sustained virologic response.15 In contrast, failure to achieve a 100-fold reduction in viral load by week 12 of therapy has a strong negative predictive value for sustained virologic response and suggests that treatment is likely ineffective and should be stopped. Table 7 lists factors that predict sustained virologic response.15,33
Table 6
Recommended Treatment for Chronic Hepatitis C Virus Infection by the Most Common Genotypes in the United States
| Genotype | Injectable | Oral | Duration (weeks) | Rate of sustained virologic response (%) |
|---|---|---|---|---|
1a and 1b | Pegylated interferon alfa-2a (Pegasys), 180 mcg weekly or Pegylated interferon alfa-2b (Pegintron), 1.5 mcg per kg weekly | Weight 165 lb (75 kg) or less: ribavirin (Rebetol), 1,000 mg daily Weight greater than 165 lb: ribavirin, 1,200 mg daily | 48 | 45 to 50 |
2 and 3 | Same as above | Ribavirin, 800 mg daily | 24 | 70 to 80 |
4 | Same as above | Weight 165 lb or less: ribavirin, 1,000 mg daily Weight greater than 165 lb: ribavirin, 1,200 mg daily | 48 | 70 |
Table 6
Recommended Treatment for Chronic Hepatitis C Virus Infection by the Most Common Genotypes in the United States
| Genotype | Injectable | Oral | Duration (weeks) | Rate of sustained virologic response (%) |
|---|---|---|---|---|
1a and 1b | Pegylated interferon alfa-2a (Pegasys), 180 mcg weekly or Pegylated interferon alfa-2b (Pegintron), 1.5 mcg per kg weekly | Weight 165 lb (75 kg) or less: ribavirin (Rebetol), 1,000 mg daily Weight greater than 165 lb: ribavirin, 1,200 mg daily | 48 | 45 to 50 |
2 and 3 | Same as above | Ribavirin, 800 mg daily | 24 | 70 to 80 |
4 | Same as above | Weight 165 lb or less: ribavirin, 1,000 mg daily Weight greater than 165 lb: ribavirin, 1,200 mg daily | 48 | 70 |
Table 7
Predictors of Sustained Virologic Response to Treatment for Chronic HCV Infection
Absence of cirrhosis |
Age 40 years or younger |
Alanine transaminase level greater than three times the upper limit of normal |
Completed 48 weeks of therapy for genotypes 1 and 4, or completed 24 weeks of therapy for genotypes 2 and 3 |
Compliance with treatment |
Female sex |
Genotypes 2 or 3 |
Lower body weight (body mass index less than 25 kg per m2) |
Low HCV RNA level (< 500,000 IU per mL) |
White race |
Table 7
Predictors of Sustained Virologic Response to Treatment for Chronic HCV Infection
Absence of cirrhosis |
Age 40 years or younger |
Alanine transaminase level greater than three times the upper limit of normal |
Completed 48 weeks of therapy for genotypes 1 and 4, or completed 24 weeks of therapy for genotypes 2 and 3 |
Compliance with treatment |
Female sex |
Genotypes 2 or 3 |
Lower body weight (body mass index less than 25 kg per m2) |
Low HCV RNA level (< 500,000 IU per mL) |
White race |
ADVERSE EFFECTS OF TREATMENT
Adherence to treatment remains a major factor influencing the rates of sustained virologic response.33,42 Discontinuation of therapy because of adverse events is common and has been reported in up to one third of patients. Approximately 50 to 60 percent of patients may exhibit self-limited influenza-like symptoms with interferon-based therapy.2 Effective management of treatment-related adverse events is essential to improve adherence to treatment; therefore, patients should be monitored closely for hematologic, renal, and thyroid abnormalities. Approximately 30 percent of patients undergoing treatment for HCV infection experience depression, emotional lability, or anger, but treatment is rarely associated with suicidal ideation or hallucinations.43 Treatment for HCV infection is contraindicated in persons with uncontrolled major depression.32 A recent randomized trial found that the overall adverse effects of pegylated interferon alfa-2b plus ribavirin (8.6 percent) and pegylated interferon alfa-2a plus ribavirin (11.7 percent) were similar.40 Adverse effects of pegylated interferon and ribavirin for the treatment of HCV infection are listed in Table 8.32
Table 8
Adverse Effects of Pegylated Interferon and Ribavirin (Rebetol) for the Treatment of Hepatitis C Virus Infection
| Frequency (%) | Adverse effects |
|---|---|
< 1 | Cardiovascular |
Angina pectoris; heart failure; myocardial infarction | |
Neurologic | |
Coma; confusion; neuropathy; retinal hemorrhage; | |
seizures; stroke; tinnitus; vision loss | |
Psychiatric | |
Acute psychosis; attempted suicide; hearing loss; | |
panic attacks; suicidal ideation | |
Other | |
Autoimmune diseases; renal, cardiac, or pulmonary failure; worsening of hepatitis | |
1 to 5 | Psychiatric |
Severe anxiety and depression; substance abuse or relapse of alcohol abuse | |
Other | |
Induction of autoantibodies; severe bacterial infection | |
> 5 | Constitutional symptoms |
Arthralgias; fatigue; fever; malaise; myalgias; nasal stuffiness | |
Dermatologic | |
Hair loss; itching; photosensitivity; rash | |
Gastrointestinal | |
Abdominal discomfort; diarrhea; nausea; poor appetite | |
Hematologic | |
Anemia; hemolysis; neutropenia; thrombocytopenia | |
Neurologic and psychiatric | |
Anger; anxiety; depression; difficulty concentrating and sleeping; emotional lability; headache; irritability; memory loss | |
Other | |
Local erythema, pain, or abscess at injection site |
Table 8
Adverse Effects of Pegylated Interferon and Ribavirin (Rebetol) for the Treatment of Hepatitis C Virus Infection
| Frequency (%) | Adverse effects |
|---|---|
< 1 | Cardiovascular |
Angina pectoris; heart failure; myocardial infarction | |
Neurologic | |
Coma; confusion; neuropathy; retinal hemorrhage; | |
seizures; stroke; tinnitus; vision loss | |
Psychiatric | |
Acute psychosis; attempted suicide; hearing loss; | |
panic attacks; suicidal ideation | |
Other | |
Autoimmune diseases; renal, cardiac, or pulmonary failure; worsening of hepatitis | |
1 to 5 | Psychiatric |
Severe anxiety and depression; substance abuse or relapse of alcohol abuse | |
Other | |
Induction of autoantibodies; severe bacterial infection | |
> 5 | Constitutional symptoms |
Arthralgias; fatigue; fever; malaise; myalgias; nasal stuffiness | |
Dermatologic | |
Hair loss; itching; photosensitivity; rash | |
Gastrointestinal | |
Abdominal discomfort; diarrhea; nausea; poor appetite | |
Hematologic | |
Anemia; hemolysis; neutropenia; thrombocytopenia | |
Neurologic and psychiatric | |
Anger; anxiety; depression; difficulty concentrating and sleeping; emotional lability; headache; irritability; memory loss | |
Other | |
Local erythema, pain, or abscess at injection site |
NEWER THERAPIES
Other interferons (consensus interferon and albinterferon alfa-2b) and ribavirin alternatives (taribavirin) are being developed to improve the effectiveness, safety, and tolerability of therapy for chronic HCV infection.44 New protease inhibitors (telaprevir and boceprevir) are actively being investigated in phase 3 clinical trials.40,45 In the future, multidrug regimens will probably be used in combination with interferon and ribavirin.
The Authors
THAD WILKINS, MD, is an associate professor in the Department of Family Medicine at the Medical College of Georgia, Augusta....
JENNIFER K. MALCOLM, DO, is a second-year resident in the Department of Family Medicine at the Medical College of Georgia.
DIMPLE RAINA, MD, is a gastroenterology fellow at the Medical College of Georgia.
ROBERT R. SCHADE, MD, is a professor in the Department of Medicine; the chief of the Division of Gastroenterology and Hepatology; and the medical director of the Special Procedures/Endoscopy Unit at the Medical College of Georgia.
Address correspondence to Thad Wilkins, MD, Medical College of Georgia, 1120 15th St., HB-4032, Augusta, GA 30912 (e-mail: twilkins@mcg.edu). Reprints are not available from the authors.
Author disclosure: Nothing to disclose.
REFERENCES
1. World Health Organization. Hepatitis C. Fact sheet N°164. Revised October 2000. http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed March 5, 2009....
2. Chou R, Clark EC, Helfand M; U. S. Preventive Services Task Force. Screening for hepatitis C virus infection: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2004;140(6):465–479.
3. Jou JH, Muir AJ. In the clinic. Hepatitis C. Ann Intern Med. 2008;148(6):ITC6-1–ITC6-16.
4. Alter MJ. Epidemiology of hepatitis C. Eur J Gastroenterol Hepatol. 1996;8(4):319–323.
5. Distributions of hepatitis C genotypes from Epidemiology of Infectious Diseases. Baltimore, Md.: Johns Hopkins Bloomberg School of Public Health; 2007. http://ocw.jhsph.edu. Accessed March 26, 2009.
6. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339(21):1485–1492.
7. Wasley A, Grytdal S, Gallagher K; Centers for Disease Control and Prevention. Surveillance for acute viral hepatitis—United States, 2006. MMWR Surveill Summ. 2008;57(2):1–24.
8. Kaur S, Rybicki L, Bacon BR, Gollan JL, Rustgi VK, Carey WD. Performance characteristics and results of a large-scale screening program for viral hepatitis and risk factors associated with exposure to viral hepatitis B and C: results of the National Hepatitis Screening Survey. National Hepatitis Surveillance Group. Hepatology. 1996;24(5):979–986.
9. Donahue JG, Muñoz A, Ness PM, et al. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med. 1992;327(6):369–373.
10. U.S. Preventive Services Task Force. Screening for hepatitis C in adults. Rockville, Md: Agency for Healthcare Research and Quality, November 2004. http://www.ahrq.gov/clinic/uspstf/uspshepc.htm. Accessed December 4, 2009.
11. Mallette C, Flynn MA, Promrat K. Outcome of screening for hepatitis C virus infection based on risk factors. Am J Gastroenterol. 2008;103(1):131–137.
12. Koff RS, Muir A. Hepatitis C. In: PIER [online database] Philadelphia, Pa.: American College of Physicians; 2008. Accessed December 1, 2008.
13. U.S. Public Heatlh Service. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep. 2001;50(RR-11):1–52.
14. Jaeckel E, Cornberg M, Wedemeyer H, et al.; German Acute Hepatitis C Therapy Group. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med. 2001;345(20):1452–1457.
15. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335–1374.
16. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349(9055):825–832.
17. Westin J, Lagging LM, Spak F, et al. Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection. J Viral Hepat. 2002;9(3):235–241.
18. Bruix J, Sherman M; Practice Guidelines Committee and American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208–1236.
19. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004;127(5 suppl 1):S27–S34.
20. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340(10):745–750.
21. Singal A, Volk ML, Waljee A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30(1):37–47.
22. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130(7):417–422.
23. Centers for Disease Control and Prevention. Reference for interpretation of hepatitis C virus (HCV) test results. http://www.cdc.gov/Hepatitis/HCV/PDFs/hcv_graph.pdf. Accesssed March 5, 2009.
24. National Institutes of Health. National Institutes of Health Consensus Development Conference statement: management of hepatitis C: 2002—June 10–12, 2002. Hepatology. 2002;36(5 suppl 1):S3–S20.
25. González V, Martró E, Folch C, et al. Detection of hepatitis C virus antibodies in oral fluid specimens for prevalence studies. Eur J Clin Microbiol Infect Dis. 2008;27(2):121–126.
26. Scott JD, Gretch DR. Molecular diagnostics of hepatitis C virus infection: a systematic review. JAMA. 2007;297(7):724–732.
27. Colin C, Lanoir D, Touzet S, Meyaud-Kraemer L, Bailly F, Trepo C; HEPATITIS Group. Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature. J Viral Hepat. 2001;8(2):87–95.
28. Patel K, Muir AJ, McHutchison JG. Diagnosis and treatment of chronic hepatitis C infection. BMJ. 2006;332(7548):1013–1017.
29. Bruno S, Stroffolini T, Colombo M, et al.; Italian Association of the Study of the Liver Disease. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology. 2007;45(3):579–587.
30. Hung CH, Lee CM, Lu SN, et al. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. J Viral Hepat. 2006;13(6):409–414.
31. Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology. 2008;47(1):43–50.
32. Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis .C. Hepatology. 2004;39(4):1147–1171.
33. Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology. 2007;46(1):37–47.
34. Rodriguez-Torres M, Sulkowski MS, Chung RT, Hamzeh FM, Jensen DM. Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population. J Viral Hepat. 2010;17(2):139–147.
35. Metwally MA, Zein CO, Zein NN. Predictors and noninvasive identification of severe liver fibrosis in patients with chronic hepatitis C. Dig Dis Sci. 2007;52(2):582–588.
36. Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T, Persing DH. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med. 1996;125(8):634–639.
37. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975–982.
38. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958–965.
39. Brok J, Gluud LL, Gluud C. Ribavirin monotherapy for chronic hepatitis C. Cochrane Database Syst Rev. 2009;(4):CD005527.
40. McHutchison JG, Lawitz EJ, Shiffman ML, et al.; IDEAL Study team. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361(6):580–593.
41. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med. 2006;355(23):2444–2451.
42. Mulhall BP, Younossi Z. Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C. J Clin Gastroenterol. 2005;39(1 suppl):S23–S27.
43. Yates WR, Gleason O. Hepatitis C and depression. Depress Anxiety. 1998;7(4):188–193.
44. Cholongitas E, Papatheodoridis GV. Review article: novel therapeutic options for chronic hepatitis C. Aliment Pharmacol Ther. 2008;27(10):866–884.
45. Njoroge FG, Chen KX, Shih NY, Piwinski JJ. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. Acc Chem Res. 2008;41(1):50–59.
Copyright © 2010 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact
afpserv@aafp.org for copyright questions and/or permission requests.
MOST RECENT ISSUE
Email Alerts
Don't miss a single issue. Sign up for the free AFP email table of contents.